# How to Slow Down Bone Loss in Women After Age 44

Hormone therapy during menopause can reduce the risk of bone loss and osteoporosis in women by nearly 70%.

This was the conclusion reached by the authors of a study presented at the ENDO 2026 annual conference.

The researchers analyzed data from 387 postmenopausal women whose bone mineral density was measured between 2021 and 2025. Postmenopause is the stage of a woman's life that begins after 12 months of complete absence of menstruation. During this time, the reproductive function of the ovaries ceases entirely, which normally occurs between the ages of 44 and 56.

Approximately one-third of the participants were receiving hormone therapy, while the rest were not undergoing such treatment.

Hormone therapy typically involves taking medications based on estrogens — female sex hormones — or their combination with progestin. With the onset of menopause, estrogen levels drop sharply, triggering accelerated bone tissue breakdown and increasing the likelihood of fractures.

The scientists compared the rates of osteopenia and osteoporosis — conditions in which bones lose density and become fragile. The results were striking: women on hormone therapy had an approximately 69% lower risk of reduced bone mineral density in the spine and femur.

This pattern held true even after adjustments for age, duration of the postmenopausal period, vitamin D levels, smoking, and other health indicators.

The study authors emphasize that many women avoid hormone therapy out of concern about side effects. However, the findings suggest that such treatment can not only alleviate the unpleasant symptoms of menopause — hot flashes, sleep disturbances — but also provide significant protection for bone tissue. Further research will be needed to fully evaluate the long-term benefits and risks of hormone therapy.